Like much U.S. primetime television, the broadcast of Oprah’s interview of Meghan Markle and Prince Harry carried a lot of pharma advertising. The sheer volume of those ads surprised many British viewers and also highlighted the volume of spending on the U.S. marketing of medicines.
US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and concluded that seven of those were not backed by any clinical evidence. The cost to the American taxpayer from those increases? Around $1.2 billion for the seven… Read More »Amgen’s Enbrel heads ICER list of unjustified US price rises
A review published in JAMA found that bills introduced into the House and Senate don’t go nearly as far as existing drug pricing regulations other countries. The researchers listed eight key lessons from six nations.